Stingray Therapeutics Company Profile

Background

Overview

Stingray Therapeutics is a biotechnology company specializing in the development of innovative immunotherapies aimed at treating various types of cancer. Established in 2018, the company is headquartered in Houston, Texas, with an additional office in Dallas, Texas.

Mission and Vision

The company's mission is to harness the full potential of the immune system by targeting both innate and adaptive immune responses to combat cancer more effectively. Their vision is to develop therapies that not only treat existing cancers but also prevent recurrence by reactivating the body's natural immune defenses.

Primary Area of Focus

Stingray Therapeutics focuses on developing small molecule inhibitors that modulate the tumor microenvironment, particularly by targeting the ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme. By inhibiting ENPP1, the company aims to restore innate immune responses, thereby enhancing the effectiveness of existing cancer treatments.

Industry Significance

In the rapidly evolving field of immuno-oncology, Stingray Therapeutics stands out by addressing the often-overlooked innate immune system. Their approach offers a novel strategy to overcome resistance mechanisms that limit the efficacy of current therapies, positioning them as a significant player in the quest for more effective cancer treatments.

Key Strategic Focus

Core Objectives

• Development of ENPP1 Inhibitors: To create potent and selective small molecule inhibitors targeting ENPP1, aiming to restore innate immune responses against tumors.

• Combination Therapies: To evaluate the efficacy of their inhibitors in combination with existing treatments, such as adaptive immune checkpoint inhibitors and radiotherapies, to enhance overall therapeutic outcomes.

Specific Areas of Specialization

• Innate Immunity Modulation: Focusing on reactivating the innate immune system to recognize and attack cancer cells.

• Tumor Microenvironment Targeting: Developing therapies that can modify the tumor microenvironment to support immune-mediated tumor destruction.

Key Technologies Utilized

• ENPP1 Inhibition: Utilizing small molecule inhibitors to block ENPP1, thereby preventing the production of immunosuppressive adenosine within the tumor microenvironment.

• Combination Therapy Strategies: Designing clinical trials that assess the synergistic effects of their inhibitors with other cancer treatments.

Primary Markets or Conditions Targeted

• Colorectal Cancer: Conducting Phase I/II studies to evaluate the combination of their ENPP1 inhibitor with checkpoint inhibitors in microsatellite stable colorectal cancer.

• Pancreatic and Gastrointestinal Cancers: Planning studies to assess the efficacy of their therapies in combination with radiotherapy for these cancers.

• Triple-Negative Breast Cancer: Exploring the potential of their inhibitors in treating this aggressive cancer subtype.

Financials and Funding

Funding History

• Pre-Seed Round (August 2020): Raised $52,300 in an initial filing from an offering of $1.5 million.

• Seed Round (February 2024): Raised $437,000 in an initial filing from an offering of $450,000.

• Seed Round (March 2023): Raised $3.95 million in an initial filing from an offering of $5.23 million.

• Debt Financing (November 2020): Secured $1.5 million in debt financing to support expansion and accelerate product development.

Notable Investors

While specific investor names are not publicly disclosed, the company's funding rounds have attracted interest from various venture capital firms and private investors.

Intended Utilization of Capital

• Clinical Development: Advancing ongoing and upcoming clinical trials, including those in colorectal cancer and other solid tumors.

• Research and Development: Expanding preclinical and clinical research to support the development of additional pipeline candidates.

• Operational Expansion: Enhancing operational capabilities to support the growing scope of clinical and preclinical activities.

Pipeline Development

Key Pipeline Candidates

• SR-8541A (ENPP1 Inhibitor): A small molecule inhibitor targeting ENPP1, currently in Phase I/II clinical trials for colorectal cancer.

Stages of Clinical Trials or Product Development

• Phase I/II Study in Colorectal Cancer: Initiated in September 2024, this study evaluates the combination of SR-8541A with checkpoint inhibitors in microsatellite stable colorectal cancer.

Target Conditions

• Colorectal Cancer: Specifically targeting microsatellite stable colorectal cancer.

• Pancreatic and Gastrointestinal Cancers: Assessing the efficacy of SR-8541A in combination with radiotherapy for these cancers.

• Triple-Negative Breast Cancer: Exploring treatment options for this aggressive cancer subtype.

Relevant Timelines for Anticipated Milestones

• September 2024: Commencement of Phase I/II study in colorectal cancer.

• 2024–2026: Utilization of a $14 million award from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund two-thirds of the colorectal cancer study.

Technological Platform and Innovation

Proprietary Technologies

• ENPP1 Inhibitors: Developing small molecule inhibitors that target ENPP1 to modulate the tumor microenvironment.

Significant Scientific Methods

• Target-Based Drug Design: Employing a strategy to create novel candidate drugs for kinases with well-validated links to cancer.

• Combination Therapy Evaluation: Designing clinical trials to assess the synergistic effects of ENPP1 inhibitors with other cancer treatments.

Leadership Team

Key Executive Profiles

• Jonathan Northrup (CEO, Co-Founder, and Board Member): With a background in biotechnology and business development, Jonathan has been instrumental in leading Stingray Therapeutics since its inception.

• Sunil Sharma (Co-Founder): A physician-scientist with expertise in oncology, Sunil co-founded the company and serves as a key figure in its scientific direction.

• Scott Jordan (Chief Business Officer): Scott brings extensive experience in business development and strategic partnerships, contributing to the company's growth and funding efforts.

• Uma Bhatt (Chief Administrative Officer): Uma oversees the company's administrative functions, ensuring efficient operations and compliance with regulatory standards.

Competitor Profile

Market Insights and Dynamics

The immuno-oncology sector is characterized by rapid innovation and intense competition, with numerous companies developing therapies targeting various aspects of the immune system. Stingray Therapeutics differentiates itself by focusing on the innate immune system, an area that has been less explored compared to adaptive immunity.

Competitor Analysis

• STINGINN, LLC: Developing drugs that modulate innate immune responses by impacting the cGAS-STING pathway.

• Aminex Therapeutics: Focused on the discovery and development of cancer immunotherapies, particularly checkpoint inhibitors.

Strategic Collaborations and Partnerships

• Translational Genomics Research Institute (TGen): Collaborating on preclinical activities for SR-8541A, including toxicology, drug product manufacture, IND filing, and clinical contracting.

• ValiRx PLC: Entered into an evaluation agreement to investigate a lead series of drug candidates for use in oncology.

Operational Insights

Stingray Therapeutics' focus on innate immunity modulation provides a unique competitive advantage, addressing a critical area in cancer immunotherapy. Their strategic collaborations with research institutions enhance their scientific capabilities and accelerate the development of their pipeline candidates.

Strategic Opportunities and Future Directions

The company plans to advance SR-8541A through several Phase II efficacy studies in combination with adaptive immune checkpoint inhibitors and different forms of radiation. This approach aims to demonstrate the breadth of utility and enhancement of standard of care in various cancers, positioning Stingray.